Canadian MDx Firm Gets Investment from OGI | GenomeWeb

NEW YORK (GenomeWeb News) – The Ontario Genomics Institute today said that it has invested an undisclosed amount in Cytognomix, a London, Ontario-based developer of cytogenetic DNA probes for potential use in diagnostics.

The firm is developing single cell DNA probes that are smaller and more densely distributed across chromosomes than probes that are currently commercially available, said OGI. These fluorescent probes can be designed to specifically target and detect chromosomal abnormalities, such as those underlying cancer.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

An opinion piece in the New York Times urges lawmakers to keep genetic protections in place.

Research funding in Canada is to remain mostly the same, ScienceInsider reports.

In Science this week: random DNA replication errors play role in cancer, and more.

The Bill and Melinda Gates Foundation embarks on an open-access publishing path.